MBX Biosciences to Participate in 43rd Annual J.P. Morgan Healthcare Conference
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Kent Hawryluk, President and CEO, will deliver a presentation on January 14th, 2025, at 2:15 p.m. Pacific Time.
The company will engage in one-on-one investor meetings during the conference. A live webcast will be available through the investors section of MBX Biosciences' website, with replay access provided approximately two hours after the event and remaining accessible for about 30 days.
MBX Biosciences (Nasdaq: MBX), un'azienda biofarmaceutica in fase clinica specializzata in terapie peptidiche di precisione per disturbi endocrini e metabolici, ha annunciato la sua partecipazione alla 43ª Conferenza Annuale J.P. Morgan Healthcare. Kent Hawryluk, Presidente e CEO, terrà una presentazione il 14 gennaio 2025, alle ore 14:15 ora del Pacifico.
L'azienda parteciperà a incontri di investimento one-to-one durante la conferenza. Sarà disponibile un webcast in diretta nella sezione investitori del sito web di MBX Biosciences, con accesso alla registrazione circa due ore dopo l'evento e rimarrà accessibile per circa 30 giorni.
MBX Biosciences (Nasdaq: MBX), una compañía biofarmacéutica en etapa clínica especializada en terapias péptidas de precisión para trastornos endocrinos y metabólicos, ha anunciado su participación en la 43ª Conferencia Anual J.P. Morgan Healthcare. Kent Hawryluk, Presidente y CEO, realizará una presentación el 14 de enero de 2025, a las 2:15 p.m. hora del Pacífico.
La compañía llevará a cabo reuniones de inversión uno a uno durante la conferencia. Habrá una transmisión web en vivo disponible en la sección de inversores del sitio web de MBX Biosciences, con acceso a la repetición aproximadamente dos horas después del evento y permanecerá accesible durante aproximadamente 30 días.
MBX 바이오사이언스 (Nasdaq: MBX)는 내분비 및 대사 장애를 위한 정밀 펩타이드 요법에 전문화된 임상 단계의 바이오제약 회사로, 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. Kent Hawryluk 사장 겸 CEO는 2025년 1월 14일 오후 2시 15분(태평양 표준시)에 발표를 진행합니다.
회사는 컨퍼런스 동안 개인 투자자 회의를 진행할 예정입니다. MBX 바이오사이언스 웹사이트의 투자자 섹션을 통해 실시간 웹캐스트가 제공되며, 이벤트 종료 약 두 시간 후에 다시 보기를 제공하고 약 30일 동안 접근할 수 있습니다.
MBX Biosciences (Nasdaq: MBX), une société biopharmaceutique en phase clinique spécialisée dans les thérapies peptidiques de précision pour les troubles endocriniens et métaboliques, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. Kent Hawryluk, Président et CEO, fera une présentation le 14 janvier 2025 à 14h15, heure du Pacifique.
L'entreprise participera à des réunions individuelles avec des investisseurs pendant la conférence. Un webinaire en direct sera disponible dans la section investisseurs du site de MBX Biosciences, avec un accès à la rediffusion environ deux heures après l'événement, et sera accessible pendant environ 30 jours.
MBX Biosciences (Nasdaq: MBX), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf präzise Peptidtherapien für hormonelle und metabolische Störungen spezialisiert hat, hat seine Teilnahme an der 43. J.P. Morgan Healthcare-Konferenz angekündigt. Kent Hawryluk, Präsident und CEO, wird am 14. Januar 2025 um 14:15 Uhr pazifischer Zeit eine Präsentation halten.
Das Unternehmen wird während der Konferenz persönliche Investorenmeetings durchführen. Ein Live-Webcast wird über den Investorenbereich der Website von MBX Biosciences verfügbar sein, mit Zugang zur Wiederholung etwa zwei Stunden nach der Veranstaltung, die etwa 30 Tage lang zugänglich bleibt.
- None.
- None.
CARMEL, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14th, 2025, at 2:15 p.m. Pacific Time. The Company will also participate in 1-on-1 investor meetings during the conference.
Live webcasts can be accessed on the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the event and will be archived on the Company’s website for approximately 30 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes its lead product candidate MBX 2109, in Phase 2 development for the treatment of chronic hypoparathyroidism (HP); MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH); and an obesity portfolio that includes MBX 4291, as well as multiple discovery and pre-clinical candidates in development for the treatment of obesity. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at www.mbxbio.com and follow it on LinkedIn.
Media Contact:
Kate Burdick
Inizio Evoke Comms
kate.burdick@inizioevoke.com
860-462-1569
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When is MBX Biosciences presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors access MBX Biosciences' J.P. Morgan Healthcare Conference presentation?
How long will the MBX Biosciences presentation replay be available?
What type of therapies does MBX Biosciences develop?
Will MBX Biosciences conduct investor meetings at the J.P. Morgan Healthcare Conference?
